No Data
Chengdu Easton Biopharmaceuticals (688513.SH): The injectable vecuronium bromide has obtained the Pharmaceutical registration certificate.
Gelonghui, January 20th丨Chengdu Easton Biopharmaceuticals (688513.SH) announced that it recently received the "Pharmaceutical Registration Certificate" issued by the National Medical Products Administration, with the pharmaceutical name: Vecuronium Bromide for Injection. The main component of Vecuronium Bromide for Injection is vecuronium bromide, indicated mainly as an adjunct to general anesthesia, used for tracheal intubation and muscle relaxation during general anesthesia.
Chengdu Easton Biopharmaceuticals (688513.SH): Wholly-owned subsidiary recognized as a high-tech enterprise.
On January 13, Gelonghui reported that Chengdu Easton Biopharmaceuticals (688513.SH) announced that its wholly-owned subsidiary, Chengdu ShuoDe Pharmaceutical Co., Ltd. (hereinafter referred to as "ShuoDe Pharmaceutical"), recently received the "High-tech Enterprise Certificate" jointly issued by the Sichuan Provincial Department of Science and Technology, the Sichuan Provincial Department of Finance, and the State Taxation Administration Sichuan Provincial Taxation Bureau. The certificate number is GR202451003551, issued on December 6, 2024, and is valid for three years. This is the first time ShuoDe Pharmaceutical has obtained the high-tech enterprise recognition.
Chengdu Easton Biopharmaceuticals (688513.SH): repurchased shares through centralized bidding trade, reaching 2% of the total share capital.
Gelonghui January 1st丨Chengdu Easton Biopharmaceuticals (688513.SH) announced that in December 2024, the company repurchased 0.2222 million shares through centralized bidding, accounting for 0.1259% of the company's current total share capital, with a maximum purchase price of 30.99 yuan/share and a minimum price of 29.85 yuan/share. The total transaction amount was 6.7647 million yuan (excluding stamp duty, transaction commissions, and other trading fees). As of the end of December 2024, the company has cumulatively repurchased 3.539 million shares through centralized bidding, accounting for the company's current total share capital.
The Recent Pullback Must Have Dismayed Chengdu Easton Biopharmaceuticals Co., Ltd. (SHSE:688513) Insiders Who Own 49% of the Company
Chengdu Easton Biopharmaceuticals (688513.SH): Participating in the national pharmaceutical centralized procurement and expected to be selected.
On December 13, Glorious Exchange reported that Chengdu Easton Biopharmaceuticals (688513.SH) announced its participation in the bidding work organized by the National Joint Procurement Office for the tenth batch of national centralized pharmaceutical procurement. According to the announcement published on December 12, 2024, on the Shanghai Sunlight Medical Procurement Network, the company’s Sodium Gluconate Injection and Nicorandil Injection are proposed to be awarded in this centralized procurement.
Chengdu Easton Biopharmaceuticals (688513.SH): The company did not implement share repurchases in November.
Gelonghui reported on December 2 that chengdu easton biopharmaceuticals (688513.SH) announced that in November 2024, the company did not implement share repurchases. As of the end of November 2024, the company has cumulatively repurchased 3,316,769 shares through centralized bidding, accounting for 1.8788% of the company’s current total share capital, with a highest purchase price of 56.05 yuan/share, a lowest price of 28.12 yuan/share, and a total transaction amount of 123,694,177.73 yuan (excluding stamp duty, transaction commissions, and other transaction costs).
Some Shareholders Feeling Restless Over Chengdu Easton Biopharmaceuticals Co., Ltd.'s (SHSE:688513) P/E Ratio
